The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ILMN | -32.1% | -68.12% | -20.44% | +427% |
| S&P | +18.33% | +108.18% | +15.79% | +385% |
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
A one-stop shop to track all the tariff and trade action from the Trump administration.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.06B | -4.9% |
| Gross Profit | $717.00M | -0.6% |
| Gross Margin | 67.83% | 3.0% |
| Market Cap | $15.10B | -9.2% |
| Market Cap / Employee | $1.46M | 0.0% |
| Employees | 10.4K | -13.7% |
| Net Income | $235.00M | 111.8% |
| EBITDA | $290.00M | -50.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $934.00M | 1.5% |
| Accounts Receivable | $716.00M | 9.0% |
| Inventory | 575 | 2.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.02B | -4.1% |
| Short Term Debt | $578.00M | -29.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 20.68% | 54.8% |
| Return On Invested Capital | -15.12% | -8.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $204.00M | 316.3% |
| Operating Free Cash Flow | $234.00M | 192.5% |
| Metric | Q2 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 12.01 | - | |||
| Price to Book | 9.70 | 9.94 | 5.32 | 6.41 | 121.33% |
| Price to Sales | 4.74 | 4.95 | 2.93 | 3.48 | -7.25% |
| Price to Tangible Book Value | 29.14 | 29.86 | 13.07 | 15.53 | -76.70% |
| Price to Free Cash Flow TTM | 38.13 | 30.53 | 14.52 | 14.43 | -69.04% |
| Enterprise Value to EBITDA | 36.50 | 84.41 | 55.69 | 56.29 | 79.00% |
| Free Cash Flow Yield | 2.6% | 3.3% | 6.9% | 6.9% | 222.97% |
| Return on Equity | -39.5% | -30.1% | -23.8% | 68.1% | -189.40% |
| Total Debt | $2.67B | $2.62B | $2.61B | $2.60B | -11.06% |
And we interview Anjay Nagpal, host of the podcast "Brokers, Bagmen, and Moles."
The sky is the limit for the leader in DNA sequencing.
The Fools reveal three stock ideas for investors interested in personalized medicine and precision oncology.
We’re pitting off gene sequencing giant Illumina against giant biotech Gilead Sciences to see which company is the better buy for long-term investors.
ILMN earnings call for the period ending September 30, 2021.
ILMN earnings call for the period ending June 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
